资金流向方面，8月25日主力资金净流入4654.46万元，近五日主力资金累计净流入11273.19万元。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 益方生物-U最新股价为42.18元，较前一交易日上涨0.55%。盘中最高触及43.79元，最低下探41.75元， 成交金额达5.54亿元。 该公司属于生物医药行业，专注于创新药物研发。目前拥有2款已上市产品，1款处于注册临床试验阶段 产品，2款处于II期临床试验阶段产品以及多个临床前在研项目。公司所有在研产品管线均拥有全球权 益。 近期公司发布2025年半年度业绩报告显示，上半年实现营收1916.38万元，同比增长28.85%。公司新申 请发明专利37项，累计获得境内外发明专利授权138项。此外，公司公告拟使用不超过10亿元闲置募集 资金进行现金管理，用于购买安全性高、流动性好的理财产品。 ...

Core Viewpoint - Real BioTech Limited has submitted its Hong Kong IPO prospectus, which has now expired after six months, with CICC as its sole sponsor [1] Company Overview - Real BioTech is an innovative biotechnology company focused on the development, manufacturing, and commercialization of innovative drugs targeting viral infections, tumors, and cardiovascular diseases [1] - The company's mission is to improve human health through genuine innovation, particularly in the fields of antiviral and antitumor therapies, addressing resistance issues in existing treatment options [1] Research and Development Platforms - Real BioTech has established a comprehensive R&D platform that includes: - A high-selectivity novel nucleoside broad-spectrum antitumor drug development platform - A TOPO1 inhibitor and XDC drug development platform - A drug target discovery and validation platform - An innovative drug design and optimization platform [1] - These platforms cover the entire drug development process, from early target screening to preclinical research, clinical trials, and subsequent optimization, providing strong technical support and systematic assurance for accelerating the discovery and development of innovative drugs [1]

(Stock Code: 1177.HK) (RMB bn) 2025 2025 Interim Results Announcement 2025.8.18 Hong Kong CONTENTS Financial Highlights Pipeline Highlights 2 Financial Highlights Both revenue and profit achieved double-digit growth 1.54 3.09 2024 H1 Continuing Operations 2025 H1 Continuing Operations Revenue 15.87 17.57 2024 H1 Continuing Operations 2025 H1 Continuing Operations Profit attributable to owners of the parent (as reported) 1.41 3.39 2024 H1 Continuing Operations 2025 H1 Continuing Operations Profit attributabl ...

Group 1 - Eli Lilly's stock has seen a remarkable increase of 9.40% over four consecutive days, driven by both favorable market conditions and strategic initiatives [1] - The company has announced a significant price increase for its weight loss drug Mounjaro in the UK, addressing international drug price disparities while seeking partnerships with private healthcare providers [1] - Mounjaro is projected to become the top-selling drug of the year, with its sales growth competing closely with Novo Nordisk's semaglutide, highlighting its effectiveness in treating diabetes and obesity [1] Group 2 - Eli Lilly has entered into a $1.3 billion agreement with Superluminal Medicines to advance the development of drugs for cardiovascular metabolic diseases and obesity [2] - This collaboration reinforces Eli Lilly's leading position in innovative drug development and showcases its commitment to bringing transformative therapies to market [2] - Viking Global, a prominent hedge fund, has recently established a position in Eli Lilly stocks, reflecting strong market confidence and positive expectations for the company's future performance [2]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company is undergoing an innovative transformation, actively seeking new business growth points in the face of intensified competition in traditional generic drug CROs. It is focusing on both innovative drug and generic drug R&D, with numerous projects in key medical fields such as oncology, autoimmune diseases, neuropsychiatric disorders, and respiratory diseases [7] - The company is expected to achieve operating revenues of 703 million, 751 million, and 823 million RMB for the years 2025, 2026, and 2027 respectively, with a projected net profit of 18 million, 55 million, and 61 million RMB for the same years [7] Financial Performance Summary - For the fiscal year 2023, the company reported an operating revenue of 1,017 million RMB, with a growth rate of 67.5%. However, a significant decline is expected in 2024 with a revenue forecast of 802 million RMB, representing a decrease of 21.2% [6][8] - The net profit for 2023 was 272 million RMB, with a growth rate of 40.1%. A loss of 53 million RMB is anticipated for 2024, followed by a recovery to 18 million RMB in 2025 [6][8] - The earnings per share (EPS) for 2023 was 2.51 RMB, but it is projected to drop to -0.49 RMB in 2024 before rebounding to 0.16 RMB in 2025 [6][8] Business Development and Innovation - The company is actively pursuing innovative drug development, with several small molecule projects underway, including BIOS-0629, BIOS-0623, BIOS-0632, and BIOS-0635. Additionally, a large molecule innovative drug targeting CD24 antibodies is in the IND pre-stage [7] - The company has made significant progress in its key innovative product targeting the H3 receptor, which addresses daytime sleepiness in patients with obstructive sleep apnea (OSA). The global prevalence of OSA is substantial, with approximately 936 million individuals affected [7] Market Position and Strategy - The company has established a broad portfolio in organoid business, covering human tumor organoids, IPSC-derived normal organoids, and toxicity prediction organoids. This has become an auxiliary tool in the drug development process [7] - The investment recommendation reflects the company's ongoing innovative transformation and its potential for future growth in the pharmaceutical sector [7]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock price increase, attributed to the acceptance of its innovative drug, TY-9591, for a key II phase registration clinical trial report at the 2025 World Lung Cancer Conference (WCLC) [1] Group 1: Company Developments - The company announced that its self-developed innovative drug, TY-9591, targets EGFR mutation-type non-small cell lung cancer (NSCLC) and has shown promising results in clinical trials [1] - TY-9591 is a highly selective small molecule inhibitor aimed at addressing unmet clinical needs for NSCLC patients with brain metastases under current treatment standards [1] Group 2: Clinical Trial Results - Research indicates that TY-9591, as a new generation EGFR-TKI, demonstrates superior efficacy in controlling brain metastases and alleviating symptoms, potentially offering a new and more effective first-line treatment option for EGFR mutation NSCLC patients with brain metastases [1]

自願公告 全面戰略合作協議 本公告乃中國抗體製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）自願作出，以知會本公司股東（「股東」）及潛在投資者有關 本集團之最新業務進展。 全面戰略合作協議 董事會欣然宣佈，於二零二五年八月十二日，本公司與中山大學香港高等研究院 有 限 公 司（「 中 山 大 學 香 港 高 等 研 究 院 」或「 SYSU -IAS 」）（ 連 同 本 公 司 統 稱「 訂 約 方」）訂立全面戰略合作協議（「合作協議」），據此，訂約方同意開展為期三年的合 作，以於生物醫學領域進行聯合研發。合作協議的主要條款概要載列如下： 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SinoMab BioScience Limited 中 國 抗 體 製 藥 有 限 公 司 （於香港註冊成立的有限公司） （股份代號：3681） 日期 二零二五 ...

Core Viewpoint - BeiGene reported a strong Q2 performance with total revenue of $1.3 billion, a 42% year-over-year increase, and a positive operating profit, indicating a successful turnaround and growth trajectory for the company [2][3][5]. Financial Performance - Q2 total revenue reached $1.3 billion, up 42% from the previous year, with core product BeiYueZe contributing $950 million, a 49% increase [3][5]. - GAAP operating profit was $87.9 million, compared to a loss of $107.2 million in the same period last year, marking a significant turnaround [4]. - Net profit for Q2 was $94.3 million, a substantial improvement from a loss of $120.4 million year-over-year [4]. - The company reported a gross margin increase to 87.4%, up from 85% in the previous year [3]. Product Performance - BeiYueZe's global revenue reached $950 million, with a notable 49% year-over-year growth, driven by strong performance in both the U.S. and European markets [8]. - The U.S. market contributed $684 million, a 43% increase, while the European market saw explosive growth of 85%, generating $150 million [8]. - The company maintains a leading market share in new patient acquisitions for BTK inhibitors [8]. Future Outlook - The company raised its full-year revenue guidance to $5-5.3 billion while maintaining expectations for positive operating profit [10]. - Over the next 18 months, the company anticipates more than 20 research and development milestones, indicating a robust pipeline [9]. - Recent regulatory advancements include priority review for Sotoclisib in China and PRIME designation for BGB-16673 in Europe, highlighting the innovative potential of its pipeline [9].

湖南麦济生物技术股份有限公司，一家专注于创新生物制剂研发的生物制药公司，近日在港股IPO之路上迈出重要一步，港交所官网公布了其整体协调人 公告的修订版。然而，这家公司的客户情况却异常独特，引发了广泛关注。 根据麦济生物招股书披露的信息，2024年全年，公司仅拥有一家客户，且这家客户并非行业巨头或知名企业，而是公司创始人、董事长张成海博士的母校 ——一所位于福建省的大学。据悉，这所大学成立于1937年，拥有悠久的历史和深厚的学术底蕴。而麦济生物当年从这家客户处获得的收入仅为2.4万 元，这一数字对于一家寻求上市的公司而言，无疑显得微不足道。 | 学校概况 | 首页>学校概况>学校简介 | | --- | --- | | 学校简介 | 学校简介 | | 学校章程 | | | 现任领导 | 福建医科大学创建于1937年，是我国建校较早的公立本科医学院校之一。80多年 | | | 来,学校秉承"勤奋、严谨、求实、创新"的校训,砥砺"改善国民卫生的先锋,东南 | | 教授风采 | 医药界的柱石"的初心，形成了"以人为本、求是至臻"的办学理念和"自强不息、追 | | 学校校标 | 求卓越"的学校精神,孕育了"崇真向善、精 ...

Financial Data and Key Metrics Changes - Net sales increased by 10.1% at constant exchange rates in Q2, primarily driven by immunology, biopharma launches, and Befortus [16][26] - Business EPS was €1.59, up 8.3%, reflecting strong sales performance and improved gross margin [18][26] - Gross margin improved by 1.5 percentage points, largely due to an improved product mix and efficiencies [16][18] Business Line Data and Key Metrics Changes - New launches generated close to €1,000,000,000 in sales, representing 10% of total sales [7][10] - Dupixent sales reached €3,800,000,000, up 21% in Q2, driven by strong demand across geographies [10][11] - Vaccine business sales increased by 10.3%, benefiting from the late flu season in the Northern Hemisphere [11][12] Market Data and Key Metrics Changes - Dupixent sales in the U.S. reached €2,800,000,000, up 22.7%, leading in new to brand prescriptions [10] - Outside the U.S., sales exceeded $1,000,000,000, driven by volume growth in key markets [10] - Anticipated sales split for flu vaccines is about 75% in Q3 and 25% in Q4, with total sales expected to decrease by a mid-teens percentage due to competitive pressures [25][26] Company Strategy and Development Direction - The company refined its 2025 sales guidance to high single-digit percentage growth at constant exchange rates, reflecting confidence in growth drivers [6][26] - The completion of the Blueprint Medicines acquisition strengthens the company's position in rare immunology diseases [13][14] - The company is committed to sustainability, aiming for all new medicines and vaccines to incorporate eco-design principles by 2025 [15][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the full-year business outlook, supported by strong performance from growth drivers [6][26] - The company is navigating uncertainties from potential U.S. tariffs and EU exports, with updates to be provided as more information becomes available [27][28] - Management remains optimistic about the pipeline and the potential for new product launches to drive future growth [41][45] Other Important Information - R&D expenses increased by 17.7% due to a lower base of comparison last year, with underlying R&D expenses up around 7% [17][18] - The company is executing a €5,000,000,000 share buyback program in 2025, with over 80% already completed [21][22] Q&A Session Summary Question: R&D transformation and pipeline progress - Management acknowledged the progress in R&D but noted that the share price is lagging, awaiting further pipeline developments [41][42] - Confidence remains in the Phase III trials and the potential for achieving €10 billion in sales by 2030 [42][43] Question: Development spend and margin outlook - R&D expenses are expected to be slightly up in H2, with SG&A increasing at half the rate of sales growth [50][52] - Management anticipates BOI margin growth alongside absolute growth in the coming years [54][56] Question: Dupixent performance in China - Dupixent has seen over 30% volume growth in China, despite pricing pressures [58][59] Question: Expectations for amlitilumab and tariffs - The company has not factored potential tariff impacts into its 2025 guidance, expecting limited effects due to existing inventory [63][64] - Amlitilumab is expected to provide comparable efficacy to existing treatments with a longer dosing interval [66][67]